Five Drugs To Watch (Assuming FDA Approval)
4 CommentsBy Ed Silverman // February 1st, 2010 // 8:21 am
Which drugs will be worth watching this year? Assuming FDA approvals come through as planned - and handicapping that possibility is trickier than ever (see here) - Barron’s compiled a list with the help of a few analysts. The presumption is that, once approval occurs, these meds will likely become blockbusters, that old-fashioned term for the biggest of sellers. And so, in no particular order, here they are…
Victoza - the recently approved diabetes drug from Novo Nordisk;
Xarelto* - a clotbuster from Bayer and Johnson & Johnson;
Prolia* - an osteoporosis treatment from Amgen;
Qnexa* - the Vivus obesity pill;
Provenge* - Dendreon’s controversial prostate cancer vaccine.
* - not yet approved by the FDA
Josh
Pradaxa, from Boehringer Ingelheim, may actually be approved before Xarelto. In the end it may help the consumer, as prices may be a little lower.
kyoto27
Ed, Provenge is listed above as “Dendreon’s controversial prostate cancer vaccine.” Following the IMPACT study, I don’t think there is anything ‘controversial’ about Provenge; but there is a lot of controversay around Dendreon and those who tried to kill the company and Provenge. In short, the numbers for Provenge all add up now and ‘controversial’ prostate cancer drug misses what Provenge is really all about–a paradigm shift in how PCa and cancer will be treated in the future.
Michael M.
And the award for “Least Novel Potential Blockbuster” goes to: Qnexa, hands down. What a joke. The FDA should simply laugh such applications out of the building.
NameIt
All these new drugs provide the opportunity to create new words. Here are some options:
Viaggravation–When you still can’t do it.
Celebrexion–A heart-breaking occasion.
Plavices–Death by a thousand cuts.
Lipitoro–One big, juicy lawn mower.
Nexia–The wrong snacks.